Oxandrolone in AIDS-wasting myopathy

AIDS

Volumn 10, Issue 14, 1996, Pages 1657-1662

  Berger, Joseph R ^a,f   Pall, Lorraine ^a   Hall, Colin D ^b   Simpson, David M ^c   Berry, Paul S ^d   Dudley, Robert ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Pacific Oaks Medical Group   (United States)

^e Gynex   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AIDS; Anabolic steroids; HIV wasting; Oxandrolone; Weight loss

Indexed keywords

ANABOLIC AGENT; OXANDROLONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE ATROPHY; MUSCLE STRENGTH; MUSCLE WEAKNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THRUSH; WEIGHT REDUCTION;

EID: 0029853892     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199612000-00010     Document Type: Article

References (16)

1. Von Roenn JR: Management of HIV-related body weight loss. Drugs 1994, 47:774-783.
2. Grunfeld C, Feingold K: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:329-337.
3. Chan ISF, Neaton JD, Saravolatz LD, Crane LR, Osterberger J, for the Community Programs for Clinical Research on AIDS: Frequencies of opportunistic diseases prior to death among HIV-infected persons. AIDS 1995, 9:1145-1151.
4. Green CJ: Nutritional support in HIV infection and AIDS. Clin Nutr 1995, 14:197-212.
5. Coodley GO, Loveless MO, Merrill TM: The HIV wasting syndrome: a review. J Acquir Immune Defic Syndr 1994, 7:681-694.
6. Kotler DP, Tierney AR, Wang J, Pierson RN, Jr: Magnitude of body cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989, 50:444-447.
7. Cat LK, Coleman RL: Treatment for HIV wasting syndrome. Ann Pharmacother 1994, 28:595-597.
8. Berger JR, Pall L, Winfield D: Effect of anabolic steroids on HIV related wasting myopathy. South Med J 1993, 86:865-866.
9. Simpson DM, Tagliati M: Neurologic manifestations of HIV infection. Ann Intern Med 1994, 121:769-785.
10. Simpson DM, Bender AN, Farrye J, et al.: Human immunodeficiency virus wasting syndrome may represent a treatable myopathy. Neurology 1990, 40:535-538.
11. Fox M, Minot A, Liddle GW: Oxandrolone: a potent anabolic steroid of novel chemical configuration. J Clin Endocrinol Metab 1962, 22:921-924.
12. Karim A, Ranney RE, Zagarella J, Maibach HI: Oxandrolone disposition and metabolism in man. Clin Pharm Ther 1973, 14:862-869.
13. Von Roenn JR, Murphy EL, Wegener N: Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol 1990, 17:13-16.
14. Jekot WF, Purdy DW: Treating HIV/AIDS patients with anabolic steroids: retrospective study. AIDS Patient Care 1993, 7:68-74.
15. Tchekmedyian NS: Clinical approaches to nutritional support in cancer. Curr Opin Oncol 1993, 5:633-638.
16. Gold J, High HA, Li Y, Michelmore H, et al.: Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996, 10:745-752.